Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

Group 1 - The core viewpoint of the news is that Nanjing South Medical Co., Ltd. (南卫股份) has experienced a decline in stock price despite a significant increase over the year, indicating potential volatility in its market performance [1][2]. - As of December 26, the stock price of Nanjing South Medical is reported at 6.29 yuan per share, with a market capitalization of 1.818 billion yuan [1]. - The company has seen a year-to-date stock price increase of 44.60%, but it has declined by 2.48% in the last five trading days and 8.31% in the last 20 days [2]. Group 2 - Nanjing South Medical's main business includes the research, production, and sales of transdermal products, medical adhesive tapes, bandages, sports protection products, first aid kits, and nursing products [2]. - The revenue composition of the company is as follows: 39.59% from adhesive bandages, 28.11% from protective equipment, 22.54% from adhesive tapes and bandages, 5.01% from dressings, 2.63% from first aid kits, and 1.71% from other products [2]. - As of September 30, the number of shareholders has decreased by 16.70% to 12,000, while the average circulating shares per person increased by 20.05% to 23,992 shares [2]. Group 3 - Nanjing South Medical has distributed a total of 77.527 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3].

证券日报网讯 12月25日，南卫股份发布公告称，公司2025年12月25日召开2025年第一次临时股东会， 审议通过《关于修订并办理工商变更登记的议案》等议案。 （文章来源：证券日报） ...

证券代码：603880 证券简称：南卫股份 公告编号：2025-032 江苏南方卫材医药股份有限公司 关于指定总经理代行财务负责人职责的公告 江苏南方卫材医药股份有限公司（以下简称"公司"）于 2025 年 12 月 25 日召开 第五届董事会第一次会议，审议通过《关于指定总经理代行财务负责人职责的议 案》。 为保证公司财务工作正常开展，在公司董事会聘任新的财务负责人之前，董事会 指定公司总经理何凌峰先生代行财务负责人职责。公司董事会将按照《公司法》及 《公司章程》等有关规定，尽快完成财务负责人选聘工作。 特此公告。 江苏南方卫材医药股份有限公司 董事会 2025 年 12 月 26 日 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 ...

江苏南方卫材医药股份有限公司 关于选举第五届董事会职工董事的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为完善公司治理结构，根据《中华人民共和国公司法》、《上海证券交易所股票 上市规则》、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》及江苏 南方卫材医药股份有限公司（以下简称"公司"）修订的《公司章程》的相关规定， 公司第五届董事会由 7 名董事组成，其中职工董事 1 名，由公司职工代表大会民主选 举产生。 公司于 2025 年 12 月 25 日召开职工代表大会，经与会职工代表审议，选举胡彩英 女士为公司董事会职工董事（简历详见附件），与公司 2025 年第一次临时股东会选举 产生的其他 6 名董事共同组成公司第五届董事会，任期自本次职工代表大会选举通过 之日起至第五届董事会任期届满之日止。 胡彩英女士符合《公司法》、《公司章程》等规定的有关职工董事的任职资格和 条件，其担任公司职工董事后，公司董事会中兼任高级管理人员职务的董事以及由职 工代表担任的董事人数总计未超过公司董事总数的二分之一，符合相 ...

证券代码：603880 证券简称：南卫股份 公告编号：2025-033 江苏南方卫材医药股份有限公司 关于修订《江苏南方卫材医药股份有限公司章程》及 办理工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江苏南方卫材医药股份有限公司（以下简称"公司"）于 2025 年 12 月 25 日召开第五届董事会第一次会议审议通过了《关于修订<江苏南方卫材医药股份 有限公司章程>及办理工商变更登记的议案》。现将有关事项公告如下： 根据《公司法》、《上市公司章程指引》等法律法规的有关规定，为进一步 完善公司治理结构，促进公司规范运作，对《江苏南方卫材医药股份有限公司章 程》（以下简称"《公司章程》"）部分条款进行修订，具体修订内容如下： | 修改前内容 | 修改后内容 | | --- | --- | | 第八条 代表公司执行公司事务的董事 | 第八条 代表公司执行公司事务的董事 | | 长为公司的法定代表人。 | 为公司的法定代表人，董事长是执行公 | | 担任法定代表人的董事长辞任的，视为 | 司事务的董事。 | ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 证券代码：603880 证券简称：南卫股份 公告编号：2025-029 江苏南方卫材医药股份有限公司 2025年第一次临时股东会决议公告 | 股东类型 | 同意 | | | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | （%） | | A 股 | 票数 119,721,135 | | | | 票数 2,600 | 比例 0.0023 | | | | 比例（%） 99.6956 | | | | | | | | | 反对 票数 362,850 | | | | | | | | | 比例 （%） 0.3021 | | | (二) 累积投票议案表决情况 | 1、出席会议的股东和代理人人数 | 43 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 120,086,585 | | 3、出席会议的股东 ...

证券代码：603880 证券简称：南卫股份 公告编号：2025-034 江苏南方卫材医药股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2026年第一次临时股东会 召开的日期时间：2026 年 1 月 12 日 14 点 45 分 召开地点：江苏省常州市武进经济开发区果香路 1 号江苏南方卫材医药股份 有限公司二楼会议室 (五) 网络投票的系统、起止日期和投票时间。 股东会召开日期：2026年1月12日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 1 月 12 日 至2026 年 1 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时 ...

证券代码：603880 证券简称：南卫股份 公告编号：2025-030 江苏南方卫材医药股份有限公司 第五届董事会第一次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 一、董事会会议召开情况 江苏南方卫材医药股份有限公司（以下简称"公司"）第五届董事会第一次会 议于 2025 年 12 月 25 日在公司会议室举行，本次会议采取现场表决与通讯表决 结合的方式召开。会议由过半数董事推举何凌峰先生主持，本次会议应参加董事 7 名，实际参加董事 7 名，参会董事同意豁免会议通知时间要求。本次会议的通 知、召开及审议程序符合《公司法》、《证券法》等法律法规及《公司章程》的有 关规定，所作决议合法有效。 二、董事会会议审议情况 经与会董事认真审议，审议通过如下议案： 1、审议通过《关于选举公司第五届董事会董事长的议案》 会议选举何凌峰先生担任公司第五届董事会董事长，任期为自本次董事会审 议通过之日起至第五届董事会届满之日止。根据《江苏南方卫材医药股份有限公 司章程》第八条规定"代表公司执行公司事务的董事长为公司的法定代表人"，公 司法定代表人将 ...

格隆汇12月25日丨南卫股份(603880.SH)公布，为保证公司财务工作正常开展，在公司董事会聘任新的 财务负责人之前，董事会指定公司总经理何凌峰先生代行财务负责人职责。公司董事会将按照《公司 法》及《公司章程》等有关规定，尽快完成财务负责人选聘工作。 ...